Joseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph R. Young sold 5,714 shares of the stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the sale, the senior vice president now owns 53,171 shares in the company, valued at $2,126,840. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Vera Therapeutics Trading Down 1.7 %

Shares of NASDAQ VERA traded down $0.85 during midday trading on Friday, reaching $47.97. The stock had a trading volume of 2,166,061 shares, compared to its average volume of 1,317,356. Vera Therapeutics, Inc. has a twelve month low of $6.05 and a twelve month high of $50.78. The company has a quick ratio of 7.71, a current ratio of 7.71 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average price is $43.21 and its 200 day moving average price is $24.75.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wedbush raised their price target on shares of Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research note on Thursday, March 21st. Oppenheimer initiated coverage on shares of Vera Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $26.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They set an “overweight” rating on the stock. Raymond James upgraded shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $29.00 to $37.00 in a research report on Friday, January 26th. Finally, Guggenheim reiterated a “buy” rating and set a $56.00 target price on shares of Vera Therapeutics in a research report on Friday, April 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $32.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its position in shares of Vera Therapeutics by 810.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company’s stock worth $38,000 after purchasing an additional 4,303 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Vera Therapeutics by 163.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock worth $45,000 after purchasing an additional 1,731 shares during the period. UBS Group AG bought a new stake in shares of Vera Therapeutics in the 1st quarter valued at $47,000. Royal Bank of Canada increased its stake in shares of Vera Therapeutics by 94.8% in the 2nd quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock valued at $54,000 after acquiring an additional 1,625 shares in the last quarter. Finally, Amalgamated Bank increased its stake in shares of Vera Therapeutics by 26.0% in the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock valued at $57,000 after acquiring an additional 864 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.